Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Österreich)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 831.9 DKK | +2.22% |
|
+6.46% | +19.17% |
| Feb. 10 | Health Care Slips on Rotation to High-Risk Sectors -- Health Care Roundup | DJ |
| Feb. 09 | Moody's Confirms Novo Nordisk on 'Very Strong' Strong Credit Metrics Expectations | MT |
| Sales 2024 * | 282B 40.87B | Sales 2025 * | 337B 48.71B | Capitalization | 3,707B 536B |
|---|---|---|---|---|---|
| Net income 2024 * | 102B 14.74B | Net income 2025 * | 120B 17.37B | EV / Sales 2024 * | 13.1 x |
| Net cash position 2024 * | 14.44B 2.09B | Net cash position 2025 * | 43.65B 6.32B | EV / Sales 2025 * | 10.9 x |
| P/E ratio 2024 * |
36.2
x | P/E ratio 2025 * |
30.4
x | Employees | 63,845 |
| Yield 2024 * |
1.46% | Yield 2025 * |
1.63% | Free-Float | 70.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | +2.22% | ||
| 1 week | +6.46% | ||
| Current month | +7.37% | ||
| 1 month | +12.74% | ||
| 3 months | +20.29% | ||
| 6 months | +33.32% | ||
| Current year | +19.17% |
1 week
783.40
833.50
1 month
703.60833.50
Current year
688.80833.50
1 year
476.05833.50
3 years
210.08833.50
5 years
155.08833.50
10 years
109.10833.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 15-03-18 |
Helge Lund
CHM | Chairman | 62 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 190 M€ | +3.64% | ||
| 10.45% | 4 M€ | +5.42% | ||
| 5.40% | 19 M€ | +2.97% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-02-09 | 831.9 | +2.22% | 2,191,243 |
| 24-02-08 | 813.8 | -1.02% | 2,486,017 |
| 24-02-07 | 822.2 | +1.07% | 3,769,135 |
| 24-02-06 | 813.5 | +0.46% | 3,908,499 |
| 24-02-05 | 809.8 | +3.63% | 4,226,296 |
Delayed Quote Nasdaq Copenhagen, February 09, 2024 at 10:59 am EST
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes treatment products (78.9%);
- rare disease treatment products (11.6%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.;
- obesity treatment products (9.5%).
Net sales are distributed geographically as follows: Europe/Middle East/Africa (25%), the United States (47.8%), North America (3.6%), China (9.2%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-03-07
- Capital Markets Day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
831.9
DKK
Average target price
744
DKK
Spread / Average Target
-10.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.17% | 536 B $ | |
| +26.97% | 666 B $ | |
| +0.01% | 377 B $ | |
| +15.07% | 318 B $ | |
| +12.33% | 307 B $ | |
| -8.02% | 207 B $ | |
| +4.05% | 206 B $ | |
| -7.92% | 191 B $ | |
| -4.27% | 156 B $ | |
| -3.63% | 117 B $ |
